Relative tumor burden predicts metastasis-free survival in pediatric osteosarcoma

• Published in: Pediatric Blood & Cancer 2008-02, Vol.50 (2), p.195-200
• Main Authors: Lee, Jun Ah, Kim, Min Suk, Kim, Dong Ho, Lim, Jung Sub, Yoo, Ji Young, Koh, Jae Soo, Lee, Soo-Yong, Jeon, Dae-Geun, Park, Kyung Duk
• Format: Article
• Language: English
• Subjects: Adolescent; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bone Neoplasms - diagnostic imaging; Bone Neoplasms - drug therapy; Bone Neoplasms - pathology; Bone Neoplasms - surgery; Chemotherapy, Adjuvant; Child; Child, Preschool; children; Cisplatin - administration & dosage; Disease-Free Survival; Doxorubicin - administration & dosage; Female; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Methotrexate - administration & dosage; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; osteosarcoma; Osteosarcoma - diagnostic imaging; Osteosarcoma - drug therapy; Osteosarcoma - pathology; Osteosarcoma - surgery; Prognosis; Radionuclide Imaging; Retrospective Studies; survival; tumor burden
• ISSN: 1545-5009; 1545-5017; 1096-911X
• DOI: 10.1002/pbc.21446

Background To analyze the significance of relative tumor burden in pediatric osteosarcoma. Methods We retrospectively reviewed 241 patients with localized pediatric osteosarcoma and measured tumor size on MR images at presentation. Absolute tumor size parameters measured on MR images were converted to relative values by dividing body surface area. Both absolute and relative size parameters were analyzed for their correlation with metastasis‐free survival (MFS). Results The 5‐year MFS was 67.5 ± 3.1%, with median follow‐up of 72 months (range, 8–205 months). In addition to poor histologic response (RR 3.24; 95% CI: 1.99–5.28; P